Donepezil is a generic prescription drug used to treat dementia due to Alzheimer’s disease. Donepezil’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...

Cholinesterase inhibitors have been shown to be helpful in patients with mild to moderate Alzheimer disease, but it is unclear whether treatment is still beneficial once patients have developed ...

Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for ...

Learn everything you need to know about Donepezil-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the ...

With the exception of the glutamate antagonist memantine, the only drug treatments currently approved by the U.S. Food and Drug Administration for treating Alzheimer disease are cholinesterase ...

October 8, 2010 — The acetylcholinesterase inhibitor donepezil (Aricept, Pfizer), used primarily to treat Alzheimer's disease (AD), significantly reduced the number of falls in Parkinson's disease (PD ...

To learn more about the drug’s serious side effects, talk with your doctor or see donepezil’s prescribing information. The side effects of donepezil are generally the same regardless of age. But ...

The acetyl cholinesterase inhibitor donepezil is one of only four FDA-approved drugs available for treating Alzheimer disease symptoms. Soon after its initial approval for mild to moderate AD in 1996, ...

Credit: Shutterstock. Adlarity is a once-weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion. The Food and Drug Administration (FDA) has ...

The acetylcholinesterase inhibitor donepezil (Aricept) failed to improve chemotherapy-related cognitive impairment (CRCI) in breast cancer survivors, a placebo-controlled trial showed. After 24 weeks ...